Intervention: human insulin inhalation powder (HIIP)
Found 10 matching trials
Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.
PHASE2
This is a research study of a study drug known as LY041001 or human insulin...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus
PHASE3
This randomized, multicenter, open-label, active-comparator, 2-arm, paralle...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes
PHASE3
This is a phase 3, open-label, randomized study to evaluate the safety and ...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD
PHASE3
Phase 3 , open-label, randomized study to evaluate the safety and efficacy ...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes
PHASE3
A study to evaluate the efficacy and safety of Human Insulin Inhalation Pow...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes
PHASE3
A study to compare Human Inhalation Powder (also known as AIR® Inhaled Insu...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP)
PHASE2
The purpose of this study is to compare intensive and standard training for...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study for Patients With Type 2 Diabetes Mellitus
PHASE2
The purpose of the study is to compare the human insulin inhalation powder ...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes
PHASE3
A study to test for non-inferiority of preprandial HIIP \[also known as AIR...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study for Patients With Type 1 Diabetes Mellitus
PHASE2
The purpose of the study is to compare the human insulin inhalation powder ...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.